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Two previous studies suggest that cigarette smoking reduces acoustic neuroma risk; however, an association
between use of snuff tobacco and acoustic neuroma has not been investigated previously. The authors conducted
a case-controlstudyinSwedenfrom2002to2007,inwhich 451 casesand710 population-basedcontrolscompleted
questionnaires. Cases and controls were matched on gender, region, and age within 5 years. The authors estimated
odds ratios using conditional logistic regression analyses, adjusted for education and tobacco use (snuff use in the
smokinganalysisandsmokinginthesnuffanalysis).Theriskofacousticneuromawasgreatlyreducedinmalecurrent
smokers (odds ratio (OR)¼ 0.41, 95% conﬁdence interval (CI): 0.23, 0.74) and moderately reduced infemalecurrent
smokers (OR ¼ 0.70, 95% CI: 0.40, 1.23). In contrast, current snuff use among males was not associated with risk of
acousticneuroma(OR¼ 0.94,95%CI:0.57,1.55).Theauthors’ﬁndingsareconsistentwithpreviousreportsoflower
acoustic neuroma risk among current cigarette smokers than among never smokers. The absence of an association
between snuff use and acoustic neuroma suggests that some constituent of tobacco smoke other than nicotine may
confer protection against acoustic neuroma.
acoustic neuroma; cigarette smoking; smoking; snuff; snus; Swedish snuff; tobacco; vestibular schwannoma
Abbreviations: CI, conﬁdence interval; OR, odds ratio; RR, risk ratio; TSNA, tobacco-speciﬁc nitrosamine.
Acoustic neuroma, also known as vestibular schwannoma, is
a benign, slow-growing tumor affecting Schwann cells of the
eighthcranialnerve.Itcomprisesapproximately8%–10%ofall
intracranial tumors(1–3). Schwann cells areperipheral nervous
system cells that produce a myelin sheath around neuronal
axons. Common presenting symptoms for acoustic neuroma
includehearingloss,tinnitus,andlossofbalance;however,large
untreatedtumorscanpotentiallyleadtobrainstemcompression,
hemorrhaging, and death, although these outcomes are rare (4).
Incidenceestimatesvaryfrom1to20casespermillionperyear
(5), with more recent estimates placing incidence between 11
and 13 cases per million per year (2). Although the incidence
appearstobeincreasingovertime(3,5–7),itisunclearwhether
this signals a true increase or is due to improved diagnostic
technology, changes in completeness of reporting, or both.
Several risk factors for acoustic neuroma have been identi-
ﬁed through previous research. The inherited genetic condi-
tion neuroﬁbromatosis type 2 has been associated with
bilaterally presenting acoustic neuroma cases; however, these
bilateral tumors account for fewer than 5% of all acoustic
neuroma diagnoses (6). Less is known about the etiology of
acoustic neuroma cases presenting unilaterally, even though
these1-sidedtumorsaccountforthemajorityofcases.Studies
ofchildrenwhoreceiveddosesofradiotherapyfortineacapitis
(8) and atomic bomb survivors (9) have linked moderate to
highdosesofionizingradiationtoincreasedacousticneuroma
risk. Risk factors including loud noise (10–12), mobile phone
use (13), and some occupational hazards (14) have also been
investigated, but these results have been inconclusive.
Two studies found a protective effect of cigarette consump-
tiononacousticneuromarisk.Schoemakeretal.(15)notedthat
ever smokers were at a reduced risk of acoustic neuroma com-
pared with never smokers (odds ratio (OR) ¼ 0.7, 95% conﬁ-
denceinterval(CI):0.6,0.9),andcurrentsmokersenjoyedeven
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April 19, 2012greaterprotection(OR¼0.5,95%CI:0.4,0.6).Usingdatafrom
the Million Women Study in Great Britain, Benson et al. (16)
conﬁrmedthatfemalecurrentsmokerswereatareducedriskof
acoustic neuroma (risk ratio (RR) ¼ 0.41, 95% CI: 0.24, 0.70),
although ever smoking data were not presented. Nicotine, the
primary psychoactive ingredient in cigarette smoke, has been
inversely associated with Parkinson’s disease (17), and both
previous acoustic neuroma studies cited the neuroprotective
effects of this chemical as 1 possible explanation of the relation
between cigarette smoke and acoustic neuroma risk.
Swedishmoistoralsnuff(alsocalledsnus)usershaveblood
levelsofnicotinethatarestrikinglysimilartothoseofcigarette
smokers,butsnuffusersattaintheselevelswithoutexposureto
combustion products (e.g., carbon monoxide and tar) (18).
Currently, there are no studies evaluating whether smokeless
tobacco is inversely related to the development of acoustic
neuroma, which could potentially provide information about
the effects of the chemicals unique to the combustion process
ontumorrisk.Thepresentstudyprovidesadditionalestimates
oftheassociationbetweencigaretteconsumptionandacoustic
neuromaandseekstodeterminewhethertheprotectiveeffects
oftobaccosmokingonacousticneuromaarealsoconferredon
Swedish snuff users.
MATERIALS AND METHODS
A population-based nationwide case-control study of acous-
tic neuroma was conducted in Sweden between September 1,
2002, and August 31, 2007.
Case ascertainment
Eligible cases were patients diagnosed with acoustic neu-
roma (InternationalClassiﬁcationofDiseases, Tenth Revision,
code C72.4, and International Classiﬁcation of Diseases for
Oncology, Second Edition, code 9560.0) between the ages
of 20 and 69 years at the time of diagnosis. Diagnoses were
either histologically conﬁrmed or based on unequivocal diag-
nostic imaging. Cases were identiﬁed in collaboration with the
hospital-basedneurosurgeryand/orotorhinolaryngologyclinics
responsibleforpatienttreatment,aswellasthroughpopulation-
basedregionalcancerregistries.Reportingofacousticneuroma
cases to the Swedish National Cancer Registry is mandatory
(19).The6 regionalcancer registries report datato the Swedish
NationalCancerRegistry,andthereforetheseregionalregistries
are updated earlier than the national registry. In addition, the
Uppsala and Linko ¨ping regions have locally established
acoustic neuroma registries at their otorhinolaryngology
clinics. These local registries are more complete than the re-
gionalcancerregistries,asclinicssometimeswaitforhistologic
conﬁrmationbeforesendingnotiﬁcationofcasestotheregional
cancerregistry,andthedelaybetweentheﬁrstacousticneuroma
diagnosisandasubsequentdiagnosticsurgicalprocedurecanbe
substantial. Also, some patients undergo stereotactic radiation
without prior histologic examination. In Stockholm for the
period from January 1, 2005, to August 31, 2007, the medical
records of all patients diagnosed with benign neoplasm of the
cranial nerves (International Classiﬁcation of Diseases,T e n t h
Revision, code D33.3) at neurosurgery clinics were scrutinized
to identify additional cases with acoustic neuroma. Because of
thescopeandthoroughnessofourcaseascertainmentmethods,
it is likely that we were able to capture a greater proportion of
diagnosed cases than most previous population-based studies.
Medical records for all cases were examined toconﬁrm the
diagnosis, to establish a date of diagnosis, and to determine
tumor laterality. The ﬁrst medical examination (usually the
ﬁrst radiologic examination) resulting in an acousticneuroma
diagnosis was used as the date of diagnosis and deﬁned as the
reference date for exposure assessment.
Patients diagnosed with neuroﬁbromatosis or tuberose
sclerosis were excluded from the study.
Controls
Two controls per case were randomly selected from the
Swedish nationwide population registry and stratiﬁed on age
in5-yearcategories,sex,andplaceofresidence(6geographic
regions corresponding to the regional cancer registries). If
neither of the 2 invited controls agreed to participate, 2 addi-
tionalcontrolswereselectedaccordingtothesameprinciples.
The reference date for controls was the date of diagnosis for
the matching case.
Data collection
Data collection started in October 2007. Permission to con-
tactthepatientwasobtainedfromthetreatingphysicianorfrom
the head of the patient’s clinic before contact was made. Each
c a s ea n dc o n t r o lr e c e i v e da ni n v itation letter with information
about the study and thereafter a mailed questionnaire regarding
environmental exposures and lifestyle information. Three
reminders, 2bymail and1bytelephone,weresentin2-week
intervals. A second copy of the questionnaire was included
with the second mail reminder. Returned questionnaires were
checked for completeness and, if needed, study participants
were contacted by telephone for missing details.
Statistical analysis
We used conditional logistic regression to estimate odds
ratios. For cigarette smoking, we analyzed each gender sepa-
rately; for snuff tobacco, we restricted analysis to male users
(78cases,119controls)becausewedidnothaveenoughfemale
snuffusersinthesample(1case,9controls)tojustifyanalysis.
We conditioned on matched sets (matched on sex, region, and
age within 5 years) and further adjusted for snuff use among
male smokers, smoking among male snuff users, and educa-
tion, using this last variable as an indicator of social class. We
also evaluated the data for residual confounding by including
age as a continuousvariable in theregressionmodels (controls
were matched to cases within 5 years of age) and found no
evidenceofthisbias(datanotshown).Dosecategoriesforboth
cigarette smoking and snuff tobacco use were similar. Ever
smokingandeversnufftobaccouseweredeﬁnedas1cigarette
daily or 1 pinch or pouch of snuff daily for 6 months or longer.
Because acoustic neuroma is a slow-growing tumor, current
use was deﬁned as those who were smoking or using snuff
regularly 1 year prior to the reference date, which was the date
of diagnosis of the case and the same date for the matched
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Conversely, past usewas deﬁned as those who had quit smok-
ing or using snuff more than 1 year prior to the reference date.
Testsfortrendwereconductedonmultilevelcategorical
v a r i a b l e sb yu s i n gt h eW a l dc h i -square test. All presented
Pvaluesare2-sided.Allanalyseswereperformedwiththe
SAS statistical software package (SAS Institute, Inc.,
Cary, North Carolina).
RESULTS
Over the course of the study period, 538 acoustic neuroma
cases and 1,089 controls were identiﬁed. Participation rates
were 84% (n¼ 451) for cases, and 65% (n¼ 710) for controls.
For the conditional logistic regression analysis, we used only
complete,informativestrata—matchedonage(within5years),
sex,andregion—leadingtoaﬁnalsampleof423casesand645
controls. The characteristics of participating cases and controls
a r es u m m a r i z e di nT a b l e1 .M a t c hing of cases and controls is
reﬂected by similarities across the matched strata between
thesegroups.Highschoolwasthehighestlevelofeducational
attainment for a greater percentage of cases than controls
(cases¼20.33%,controls¼15.17%)and,therefore,aswould
beexpected,fewercasesthancontrolshadattendeduniversity
and beyond (cases ¼ 26.24%, controls ¼ 29.77%); however,
we adjusted for education so these distributional differences
are accountedfor inthe analysis.Additionally,lower levels of
educational attainment have recently been associated with
a decreased risk of acoustic neuroma (20), further justifying
adjustmentforthiscovariate.Maritalstatuswassimilarbetween
cases and controls; thus, we did not adjust for it.
A strong protective association of current smoking with
acoustic neuroma risk was found among males (OR ¼ 0.41,
95% CI: 0.23, 0.74) (Table 2), and a less potent association,
with a wider conﬁdence interval, was found among females
(OR¼0.70,95%CI:0.40,1.23).Pastsmokingwasnotrelated
to acousticneuroma risk for either gender, so the reduced risk
associated with ever smoking is attributable to current
smoking.
Men with 20 or more pack-years of smoking showed
a decreased acoustic neuroma risk (OR ¼ 0.46, 95% CI:
0.26, 0.81) (Web Table 1, which is posted on the Journal’s
website (http://www.aje.oxfordjournals.org/)). However,
Table 1. Characteristics of Acoustic Neuroma Cases and Controls, Sweden, 2002–2007
a
Characteristics
Men Women All
Cases Controls Cases Controls Cases Controls
No. % No. % No. % No. % No. % No. %
Age at reference date, years
<35 21 9.09 36 10.03 18 9.38 25 8.74 39 9.22 61 9.46
35–44 29 12.55 41 11.42 28 14.58 43 15.03 57 13.48 84 13.02
45–54 57 24.68 83 23.12 47 24.48 75 26.22 104 24.59 158 24.50
55–64 89 38.53 138 38.44 69 35.94 104 36.36 158 37.35 242 37.52
>64 35 15.15 61 16.99 30 15.63 39 13.64 65 15.37 100 15.50
Region
Stockholm 43 18.61 69 19.22 39 20.31 57 19.93 82 19.39 126 19.53
Uppsala 58 25.11 84 23.40 50 26.04 70 24.48 108 25.53 154 23.88
Umea ˚ 24 10.39 40 11.15 13 6.77 23 8.04 37 8.75 63 9.77
Linko ¨ping 38 16.45 62 17.27 47 24.48 72 25.17 85 20.09 134 20.78
Go ¨teborg 39 16.88 57 15.88 30 15.63 45 15.73 69 16.31 102 15.81
Lund 29 12.55 47 13.09 13 6.77 19 6.64 42 9.93 66 10.23
Marital status
Single 27 11.69 50 13.93 16 8.33 34 11.89 43 10.17 84 13.02
Married/cohabitating 180 77.92 284 79.11 153 79.69 200 69.93 333 78.82 484 75.04
Separated/divorced 16 6.93 17 4.74 14 7.29 25 8.74 30 7.09 42 6.51
Widowed 8 3.46 8 2.23 9 4.69 27 9.44 17 4.02 35 5.43
Highest attained
educational level
Elementary school 65 28.14 108 30.08 50 26.04 76 26.57 115 27.19 184 28.53
2-year secondary 61 26.41 92 25.63 49 25.52 68 23.78 110 26.00 160 24.81
Minimum 3-year high school 57 24.68 61 16.99 29 15.10 42 14.69 86 20.33 103 15.17
University/college or
postgraduate
47 20.35 94 26.18 64 33.33 98 34.22 111 26.24 192 29.77
a The number of observations throughout the table varies by characteristic category because of missing values.
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Table
2.
Continued44% of these men were current smokers, whereas current
smokers comprised only 10% of male smokers with fewer
than 20 pack-years. To determine whether the effect of
smoking pack-years on acoustic neuroma risk was attributable
to the dose and duration of cigarette consumption or to current
smoking, we dichotomized both male and female current
smokers for whom we could calculate pack-years (n ¼ 157)
into 2 categories: fewer than 20 packyears and greater than
or equal to 20 pack-years, based on the median pack-years
found among ever smoker controls (Web Table 1). We
observed differences of association between the genders.
Among men, most of the dose-response association was
found among former smokers (although the number of current
smokers among cases with fewer than 20 pack-years is small).
Among women, there appeared to be no dose-response
association.
In Table 2, we also examined the age at which participants
began smoking, years since started smoking, total years of
smoking, and number of years since stopped smoking but
foundnorelationbetweenthesefactorsandacousticneuroma
risk.
Weevaluatedsnufftobaccouseonlyamongmales,because
the sample size for female snuff tobacco users was too small
for meaningful inferences. There was no relation between
havingeverusedsnufftobacco,orbeingacurrentorpastuser,
and acoustic neuroma risk when compared with never snuff
users (Table 3). We also examined the age at ﬁrst snuff use,
years since started using snuff, total years of usage, and years
since stopped using snuff, and we found no association with
acoustic neuroma risk when comparing the distribution of
these variables with that among never snuff users.
DISCUSSION
We found that the risk of acoustic neuroma was greatly
reduced in male current smokers and moderately reduced in
female current smokers. A previous study that included both
men and women did not report gender-speciﬁc results; how-
ever, our results for ever smokers for both genders combined
are similar to this study (15). Our results for female smokers
are in the same direction as those reported in the Million
Women Study (16), where the risk ratio was 0.41 (95% CI:
0.24, 0.70) for current versus never female smokers, although
our effect estimates areweakerinmagnitude. We observedno
evidence of a role for snuff tobacco consumption in acoustic
neuroma etiology. The disparity between the effects of smok-
ingtobaccoandsnuffuseonriskofacousticneuromasuggests
thatthe potentially protective beneﬁtsofsmoking tobacco are
caused by something other than nicotine, the most prominent
shared ingredient of the 2 tobacco intake methods.
Aspreviouslynoted,ourresultsforcigarettesmokingmirror
those of previous studies. Using case-control data from the
Nordic countries and the United Kingdom, Schoemaker et al.
(15)foundeversmokingversusnever smokingtobeprotective
against acoustic neuroma (OR ¼ 0.7, 95% CI: 0.6, 0.9). These
authors reported an even stronger inverse relation when com-
paringcurrentsmokerswithneversmokers(OR¼0.5,95%CI:
0.4, 0.6). Schoemaker et al. did not present separate data for
men and women; however, their reported odds ratios for ever
smoking versus never smoking and current smoking versus
never smoking are strikingly similar to the combined odds
ratios in our study.
Our study did not conﬁrm all of the ﬁndings of Schoemaker
et al. (15). We found neither an inverse dose-response relation
between cigarette smoking pack-years and acoustic neuroma
risk (the Schoemaker et al. Ptrend < 0.001) nor a dose-response
relation linking the total number of years smoked to decreased
riskofacousticneuroma(theSchoemakeretal.Ptrend<0.001).
However, the study by Schoemaker et al., while similar to ours
intermsofcasesamplesize,hadgreaterthan3timesthenumber
of controls. It is possible that their increased statistical power
allowed them to identify effects that we could not.
Data from the Million Women Study in Great Britain were
alsousedtoevaluatetherelationbetweencigarettesmokingand
acoustic neuroma risk. In a prospective cohort, Benson et al.
(16) found that current smokers enjoyed protection against
acousticneuroma(RR¼0.41,95%CI:0.24,0.70).Inaddition,
the investigators detected a dose-response relation among cur-
rent smokers: Women who smoked 15 or more cigarettes per
day had a lower risk of acoustic neuroma (RR ¼ 0.27, 95% CI:
0.11, 0.66) than did women who smoked fewer than 15 ciga-
rettes per day (RR ¼ 0.53, 95% CI: 0.28, 1.00). It should be
noted that, because this was a prospective study of a rare con-
dition, the case sample sizewas small: Risk ratios were derived
from data on only 16 current smokers (11 of whom smoked
f e w e rt h a n1 5c i g a r e t t e sp e rd a y ,a n d5o fw h o ms m o k e d1 5o r
more cigarettes per day), although they contributed over 10.2
million person-years of follow-up time. In contrast, the present
study had an appreciably larger sample of cases from which to
draw, including 191 female acoustic neuroma cases, 25 of
whom were current smokers 1 year before their diagnoses. In
addition, unlike the analyses of Benson et al., all of our partic-
ipants were matched onvariables representing age, gender, and
region, which increased the statistical power of our analyses.
It should be noted that there are important physical and
chemical differences between Swedish and American
snuff. American companies produce 3 different types of
snuff (chewing tobacco, moist snuff, and dry snuff), whereas
Swedish companies produce moist snuff almost exclusively
(21). American snuff is fermented during the manufacturing
process, potentially leading to increased levels of tobacco-
speciﬁc nitrosamines(TSNAs),whichareknowncarcinogens
(21).Incontrast,Swedishsnufftobaccoistraditionallytreated
withsteam for a periodof24–36 hours,ina process similar to
pasteurization,whichcanlargelypreventmicrobialactivation
ofTSNAs.Onestudyreportedthat,althoughsampledSwedish
snuffhadbetween2.8and11.2lgofTSNAspergramofmoist
snuff,Americansnuffhadbetween3.7and127.9lgofTSNAs
pergram(22).Inlightofthesedifferences,thepresentstudy’s
ﬁndings apply only to Swedish snuff.
Peak blood nicotine levels are similar among habitual cig-
arette smokers and Swedish snuff users (18), so our ﬁndings
therefore suggest that nicotine is not the source of acoustic
neuroma risk reduction among cigarette smokers. A notable
difference between cigarette smoking and snuff use is that,
while the nicotine in snuff is absorbed orally, cigarettes rely
oncombustiontodelivernicotine.Cigarettecombustion,with
its byproducts of carbon monoxide and other chemicals,
has a hypoxic effect on human tissue (23). A recent study
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and reoxygenation on Schwann cells in vitro, found that
hypoxia and reoxygenation induce apoptosis and reduce
cell viability. Because acoustic neuroma is characterized
byanoverproliferation of Schwann cells, this isapossible
explanation as to why cigarette smoke protects against
acoustic neuroma risk and snuff use does not.
Nonetheless, several studies have investigated the antiin-
ﬂammatory effects of nicotinetherapy, thus potentially impli-
cating nicotine as the chemical agent responsible for reduced
Table 3. Risk of Acoustic Neuroma in Relation to Regular Snuff Use, Sweden, 2002–2007
a,b
Factor
Men
Cases Controls
OR
c 95% CI
No. % No. %
Ever snuff user
No 152 66.09 239 66.76 1.0
d
Yes 78 33.91 119 33.24 0.99 0.65, 1.51
Snuff user status
Former snuff user 37 16.09 44 12.29 1.22 0.71, 2.10
Current snuff user
e 40 17.39 71 19.83 0.94 0.57, 1.55
Age started using snuff, years
<15 10 4.35 11 3.07 1.21 0.36, 4.07
15–19 28 12.17 42 11.73 0.95 0.53, 1.68
 20 40 17.39 66 18.44 1.01 0.60, 1.68
Ptrend (all subjects) 0.58
Ptrend (ever snuff users) 0.98
Years since started using snuff
<10 7 3.04 16 4.47 0.80 0.31, 2.06
10–19 15 6.52 25 6.98 1.00 0.45, 2.19
20–29 26 11.30 25 6.98 1.60 0.77, 3.28
 30 30 13.04 53 14.80 0.86 0.51, 1.65
Ptrend (all subjects) 0.47
Ptrend (ever snuff users) 0.63
Total years using snuff
<10 19 8.26 30 8.38 0.913 0.47, 1.77
10–19 21 9.13 29 8.10 1.20 0.60, 2.42
20–29 16 6.96 24 6.70 0.96 0.45, 2.06
 30 16 6.96 27 7.54 0.91 0.46, 1.82
Ptrend (all subjects) 0.65
Ptrend (ever snuff users) 0.97
Years since stopped using snuff
 20 12 5.22 12 3.35 1.29 0.53, 3.13
10–19 7 3.04 16 4.47 0.64 0.24, 1.68
>1–9 16 6.96 15 4.19 1.56 0.68, 3.59
Current snuff user
e 40 17.39 71 19.83 0.89 0.54, 1.47
Ptrend (all subjects) 0.59
Ptrend (ever snuff users) 0.57
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Snuff use is deﬁned as at least 1 packet or dose daily for 6 months or longer.
b The number of observations throughout the table varies by snuff use category because of missing values. Each factor in the table represents
a different regression coefﬁcient with different covariates.
c Odds ratios from conditional logistic regression models stratiﬁed by matched set. Cases and controls were matched on gender, age (within 5
years at the reference date), and region. Odd ratios were adjusted for highest level of education and smoking status as of the reference date (never
user, past user, and current user).
d Reference category for the entire table.
e Current snuff use odds ratios are not identical because they are based on regressions with different covariates.
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investigators treated intratracheal lipopolysaccharide (50 lg)-
challenged mice with nicotine doses (either 0.2 or 0.4 mg/kg,
subcutaneously)(25).After24hours,thestudyauthorsobtained
bronchoalveolar lavage ﬂuid and found attenuated levels of in-
ﬂammatory cells. In a separate in vivo study, nicotine adminis-
tration (2 mg/kg, subcutaneously) suppressed the severity of
experimental autoimmune encephalomyelitis (26). Although
our snuff ﬁndings do not mirror the effects found in these
studies,thisattenuatedinﬂammatoryresponsesuggeststhat
nicotinecouldbethechemicalsubstanceinducingtheprotective
effects of smoking tobacco on acoustic neuroma genesis. Odds
ratios in the present study may have been distorted by selection
bias, a source of bias in case-control studies. Potential controls
(65% participated) were less likely to agree to participate in the
study than were cases (84% participated). Nonparticipants are
more likely to be characterized by low socioeconomic status
(27) that is also associated with cigarette and snuffintakes (28).
At the same time that socioeconomic status is associated with
cigarette smoking and snuff use, it is also probably indepen-
dently related to acoustic neuroma risk, making it a potentially
confounding variable. The relations among socioeconomic sta-
tus,education,tobaccouse,andacousticneuromaarecomplex;
however, it is probably safe to assume that equal case-control
participation would have strengthened the inverse association
between cigarette smoking and acoustic neuroma, because
smokers were less likely to participate than were nonsmokers.
Itisalsopossiblethatourfailuretoobserveaneffectofsnuffuse
is attributable to selection bias, which might have been more
strongly affected by unequal case-control selection than was
cigarette consumption.
Another potential source of distortion is detection bias,
deﬁned as the preferential diagnosis of individuals with higher
socioeconomic status. As noted before, thosewith lower socio-
economic status are more likely to be smokers and snuff users
(28).Thus,ifpresent,thisbiaswouldartiﬁciallylowersmoking
and snuff use rates in our case sample and lead to a spurious
inverserelationbetweenbothsmokingandsnuffuseandacous-
ticneuroma.Althoughwefoundastronginverserelationamong
male smokers, we found no relation among male snuff users,
indicating that detection bias did not inﬂuence our results.
It is worth noting that our ﬁndings, as in any observational
study, may reﬂect both causal patterns and biases. We therefore
restrict our discussion to the strongest results and await further
conﬁrmation from subsequent studies to develop detailed de-
scriptions of underlying mechanisms. We thus avoid ‘‘overin-
terpreting’’ our data or constructing causal explanations for
random or systematic bias. For example, although previous
studies have not presented separate odds ratios for men and
women with regard to cigarette smoking and acoustic neuroma
risk, we felt that the difference in the magnitude of the effects
was large enough to justify reporting. However, becausewe are
the ﬁrst to report such a difference, we are not surewhether this
reﬂectsatruegenderdifferenceorisduetosomeformofbiasor
random variation and, thus, have refrained from forming a pre-
mature biologic justiﬁcation when none is clearly apparent.
The public health hazards associated with cigarette smoking
areboth wellknown andwell documented;assuch,itis notour
intention to endorse smoking as a means of protection against
acoustic neuroma development. However, the consistency with
which cigarette smoking has been shown to reduce acoustic
neuroma risk, in both the present study and those of others
(15, 16), provides rare clues into the etiology of a tumor about
which relatively little is known. Accordingly, we encourage
researchers to investigate the mechanism by which some con-
stituent of tobacco smoke appears to reduce acoustic neuroma
risk.
Further studies are needed to conﬁrm the difference in the
magnitudeofeffectsfoundbetweenmenandwomeninrelation
tosmokingandriskofacousticneuroma.Additionally,oursnuff
results for men should be validated, and the relation between
snuff use among women and acoustic neuroma risk should be
analyzed. To test the effects of hypoxia on the risk of acoustic
neuroma, investigators in future observational studies could
identify the rates of acoustic neuroma at disparate altitudes, to
see whether higher, less oxygen-rich environments reduce
acoustic neuroma risk.
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